Vyome Holdings (HIND) Intangibles (2020 - 2026)

Vyome Holdings (HIND) posted quarterly Intangibles of $314191.0 for Q1 2026, little changed quarter-over-quarter from $314191.0 in Q4 2025.

Vyome Holdings (HIND) Intangibles (2020 - 2026) Analysis & Trends

Vyome Holdings' Intangibles history runs 7 years deep, the most recent figure standing at $314191.0 for Q1 2026.

In Q1 2026, Intangibles changed N/A year-over-year to $314191.0; the TTM figure through Mar 2026 stood at $314191.0 (changed N/A YoY), while the FY2025 annual figure was $314191.0, changed 0.0% from the prior year.
Intangibles for Q1 2026 stood at $314191.0, roughly flat from $314191.0 in the prior quarter.
The five-year high for Intangibles was $20.4 million in Q1 2022, with the low at $249000.0 in Q1 2023.
The 5-year median for Intangibles is $314191.0 (2024), against an average of $5.4 million.
The sharpest annual moves came in 2022 and 2023: Intangibles surged 637.59% in 2022, then sank 98.78% in 2023.
Vyome Holdings' Intangibles stood at $260000.0 in 2022, then surged by 2381.15% to $6.5 million in 2023, then plunged by 95.13% to $314191.0 in 2024, then changed by 0.0% to $314191.0 in 2025, then changed by 0.0% to $314191.0 in 2026.
Business Quant data shows HIND's Intangibles at $314191.0 in Q1 2026, $314191.0 in Q4 2025, and $314191.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	266.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	93.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Vyome Holdings	16.07 Mn	8.18 Mn	11,658.00	314,191.00

Download Data